Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug joins fight against pancreatic cancer in early trial

NCT ID NCT06203821

Summary

This early-stage study is testing whether adding an experimental drug called NP137 to standard chemotherapy before and after surgery can help control pancreatic cancer. The goal is to see if NP137 can change the tumor's behavior to make it less aggressive and potentially delay its spread. The study will enroll about 25 adults with pancreatic cancer that surgeons believe can be removed.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Rochester

    Rochester, New York, 14642, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.